KPL-387 — Clinical data readout
H2 2027
Kiniksa is enrolling and dosing patients in the Phase 3 pivotal trial of KPL-387 in recurrent pericarditis, PASTORALE, and expects data in the second half of 2027.Source filing
KNSA biotech catalysts & pipeline
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC · Data as of 2026-10-27